Form 4: CytomX Therapeutics SVP Marcia Belvin Reports Routine Stock Transactions

CytomX Therapeutics, Inc.'s Senior Vice President and Chief Scientific Officer, Marcia Belvin, reported the vesting of performance stock units and a subsequent sale of shares to cover tax obligations.

Summary

• Marcia Belvin, SVP, Chief Scientific Officer of CytomX Therapeutics, Inc. (CTMX), reported transactions involving the company's common stock.
• On June 13, 2025, 37,500 performance stock units (PSUs) granted on February 2, 2023, vested, resulting in the acquisition of 37,500 shares of common stock.
• Following the PSU vesting, Ms. Belvin beneficially owned 286,136 shares, which includes 158,958 restricted stock units.
• On June 16, 2025, Ms. Belvin sold 13,884 shares of common stock at a price of $2.689 per share.
• This sale was conducted solely to satisfy tax or other government withholding obligations related to the vesting of the PSUs.
• After these transactions, Ms. Belvin's beneficial ownership stands at 272,252 shares of common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine insider transaction related to executive compensation (vesting and tax-related sale), which is a standard occurrence and does not indicate a significant positive or negative shift in company fundamentals or executive confidence.

Positives

• The vesting of 37,500 performance stock units indicates the achievement of performance criteria, leading to the realization of executive compensation.

Negatives

• A portion of the acquired shares (13,884 shares) was sold, reducing the direct beneficial ownership of the executive, although this was for tax purposes.

Future Outlook

This document, a Form 4, does not provide information regarding the company's future outlook or guidance.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, common across all publicly traded companies, and does not provide specific insights into broader industry trends or competitive landscape beyond the executive's compensation structure.

Stakeholder Impact

• Shareholders: The report details a routine executive compensation event, which is part of the company's established compensation structure. The sale of shares for tax purposes is a common practice and does not typically signal a change in executive confidence or company prospects.

Key Dates

Keywords

CytomX Therapeutics, CTMX, Form 4, Insider Transaction, Executive Compensation, Performance Stock Units, PSU Vesting, Stock Sale, Tax Withholding